KRASq

KRASq is a G-quadruplex-forming synthetic oligonucleotide designed to target the promoter region of the KRAS oncogene. Developed by researchers at the University of Louisville, KRASq mimics the G-rich genomic sequence within the KRAS promoter, enabling it to form stable G-quadruplex structures or bind to the complementary C-rich strand of the promoter DNA. This interaction inhibits transcription, leading to the downregulation of KRAS gene expression and subsequent inhibition of cancer cell proliferation. KRASq has been evaluated in preclinical studies for its potential therapeutic efficacy in breast cancer, particularly triple-negative breast cancer (TNBC) cell lines such as MDA-MB-231, where it demonstrates selective growth inhibitory activity.

Other names

KRAS G-quadruplex oligonucleotideKRASq oligonucleotide